Carmichael Hill & Associates’s Avadel Pharmaceuticals AVDL Stock Holding History

Carmichael Hill & Associates’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$275K	Hold	21,000	–	–	0.1%	156
2024 Q2	$295K	Hold	21,000	–	–	0.12%	138
2024 Q1	$355K	Hold	21,000	–	–	0.14%	118
2023 Q4	$297K	Hold	21,000	–	–	0.12%	134
2023 Q3	$216K	Hold	21,000	–	–	0.1%	155
2023 Q2	$346K	Hold	21,000	–	–	0.15%	112
2023 Q1	$192K	Hold	21,000	–	–	0.09%	161
2022 Q4	$150K	Hold	21,000	–	–	0.08%	195
2022 Q3	$105K	Hold	21,000	–	–	0.06%	218
2022 Q2	$51K	Buy	21,000 +12,000	+133%	+$49.3K	0.03%	326
2022 Q1	$61K	Buy	9,000 +1,000	+13%	+$6.87K	0.03%	318
2021 Q4	$65K	Hold	8,000	–	–	0.03%	321
2021 Q3	$78K	Hold	8,000	–	–	0.04%	276
2021 Q2	$54K	Hold	8,000	–	–	0.03%	334
2021 Q1	$72K	Hold	8,000	–	–	0.04%	275
2020 Q4	$53K	Buy	8,000 +2,000	+33%	+$12.5K	0.03%	305
2020 Q3	$30K	Hold	6,000	–	–	0.02%	368
2020 Q2	$48K	Buy	6,000 +2,000	+50%	+$17.6K	0.04%	280
2020 Q1	$32K	Hold	4,000	–	–	0.03%	317
2019 Q4	$30K	Buy	+4,000	New	+$21.1K	0.02%	341

Other funds holding AVDL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Carmichael Hill & Associates's AVDL Position: Q3 2024 in Review

Carmichael Hill & Associates held its Avadel Pharmaceuticals (AVDL) position steady in Q3 2024 at 21,000 shares worth $275K. The position accounts for 0.1% of the portfolio, ranked #156.

Carmichael Hill & Associates first reported a position in AVDL in Q4 2019 and has held it in 20 quarters since. The position peaked at $355K in Q1 2024. 176 funds tracked by Wall St. Rank hold AVDL as of Q3 2024.

Carmichael Hill & Associates held 21,000 shares of Avadel Pharmaceuticals worth $275K as of Q3 2024.
Carmichael Hill & Associates left its Avadel Pharmaceuticals share count unchanged in Q3 2024.
Avadel Pharmaceuticals made up 0.1% of Carmichael Hill & Associates's portfolio in Q3 2024, its #156 holding.
Carmichael Hill & Associates first reported a position in Avadel Pharmaceuticals in Q4 2019 and has held it in 20 quarters since.
Carmichael Hill & Associates's Avadel Pharmaceuticals position peaked at $355K in Q1 2024.
176 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2024.

Based on Carmichael Hill & Associates's 13F filing for Q3 2024, filed 29 Oct 2024.